Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phosphonoethylamine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Phosphonoethylamine (PEA) is an artificial substrate for CTP-phosphoethanolamine cytidylyltransferase (Pcyt2), a rate-limiting enzyme in phosphatidylethanolamine (PE) synthesis. It is a phosphonate analog of phosphoethanolamine (PEtn), the natural Pcyt2 substrate, where the phosphorus group is linked by a C-P bond. PEA is a biogenic compound found in various organisms, including humans. It is being investigated for its therapeutic potential in reversing nonalcoholic steatohepatitis (NASH) by stimulating flux through the CDP-ethanolamine Kennedy pathway, thereby ameliorating the consequences of Pcyt2 deficiency.
02
Targets
PCYT2 (Phosphate cytidylyltransferase 2, ethanolamine)
Beyond the preview
Go deeper on phosphonoethylamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phosphonoethylamine.